MP-1, Inc. Changes Name to Phoenix Biosciences, Inc. to Reflect Company Growth.
Phoenix Biosciences, Inc., focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS, announced today that it has officially changed its name from MP-1, Inc. to Phoenix Biosciences, Inc. This reflects the company's growth and its continued focus on testing its compound drug PBS119, which was developed as a unique approach for treating HIV/AIDS.
PBS119 takes a different approach than the current drugs used to treat HIV/AIDS. Instead of attacking the virus itself, this treatment uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. In preliminary pilot tests conducted by Phoenix Biosciences, PBS119 demonstrated positive results, which provided the company with the added assurance to continue with their unique approach.
"With an increased focus on HIV/AIDS, our new name Phoenix Biosciences represents a turning point for the company," said Dr. Robert Keller, Chairman, CEO and CSO of Phoenix Biosciences. "An estimated 40 million people are infected with HIV and we are committed to accelerating the process allowing us to offer a new, affordable and non-toxic treatment for HIV."
Phoenix is currently in the process of raising funds in order to conduct clinical trials. The company is determined to complete these clinical trials and gain FDA approval to begin offering patients this treatment worldwide.
About Phoenix Biosciences, Inc.
Phoenix Biosciences, Inc. is focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS in the last decade. The company has developed the compound drug PBS119 as a different approach for treating the HIV virus. This approach uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company owned by parent company Immune Balance Technologies, LLC (IBT). In addition, IBT owns Vit-Immune, which develops, tests and markets nutritional supplements that assist in the general well-being of people and enhances the benefits of PBS119 for those suffering from chronic immune diseases including HIV/AIDS. For more information about Phoenix Biosciences, Inc. or Vit-Immune, please email email@example.com or visit www.robkellermd.org
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 17, 2004|
|Previous Article:||TIAX Chosen by DOE for Hydrogen Storage Research Project; $1.5 million project will assess hydrogen storage technologies in an effort to make...|
|Next Article:||Telkonet Highlights Powerline Communications at 2004 NMCI Industry Symposium.|